comparemela.com

Latest Breaking News On - Medacta shoulder system - Page 3 : comparemela.com

Adhoc: Medacta Group SA: 2022 Full Year Unaudited Top-Line Figures release / Today s call at 4:00pm CET

Medacta Group SA / Key word(s): Annual Results Medacta Group SA: 2022 Full Year Unaudited Top-Line Figures release / Today's call at 4:00pm CET 03-Feb-2023 / 07:00 CET/CEST Release of an ad hoc announcement

Adhoc: Medacta Group SA: Medacta Group SA reports 19 0% growth of half-year revenue

Medacta Group SA / Key word(s): Sales Result Medacta Group SA reports 19.0% growth of half-year revenue 29-Jul-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

EQS-Adhoc: Medacta Group SA: Medacta Group reports strong revenue growth of 21 4% in 2021

EQS-Ad-hoc: Medacta Group SA / Key word(s): Sales Result Medacta Group SA reports strong revenue growth of 21.4% in 2021 20-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant

EQS-Adhoc: Medacta Group SA reports strong revenue growth of 21 4% in 2021

EQS-Ad-hoc: Medacta Group SA / Key word(s): Sales Result Medacta Group SA reports strong revenue growth of 21.4% in 2021 20-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to

EQS-Adhoc: Medacta Group SA reports 35 4% growth at constant currency of half-year revenue and revises upward the revenue target for 2021

(2) EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Sales Result Medacta Group SA reports 35.4% growth at constant currency of half-year revenue and revises upward the revenue target for 2021 20-Jul-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Press Release - Ad-hoc announcement pursuant to Art. 53 LR Medacta Group SA reports 35.4% growth at constant currency of half-year revenue and revises upward the revenue target for 2021 - 1H 2021 revenue increased to Euro 177.5 million, or 35.4% at constant currency (31.7% reported) vs 1H 2020. - The growth was driven by significant carry-over and customer acquisition, in addition to faster-than-expected normalization of surgery activities, with positive contributions from all business lines and geographies.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.